EGFR Mutation Status and TKI Therapy in Patients with Advanced Vulvar Cancer: Clinical Observations - Open Access Library Journal

OALibJ > Vol.4 No.10, October 2017

EGFR Mutation Status and TKI Therapy in Patients with Advanced Vulvar Cancer: Clinical Observations ()

HTML XML

Download as PDF (Size: 398KB) PP. 1-10

DOI: 10.4236/oalib.1103956 431 Downloads 1,057 Views Citations

Author(s)

Kun Liu¹, Yong Yang^2*, Cunde Wang³, Yufeng Wang¹, Ying Zhu¹

Affiliation(s)

¹Department of Cadres Medical, The Affiliated Tumor Hospital of Kunming Medical University, Kunming, China.
²Department of Urology, The Affiliated Tumor Hospital of Kunming Medical University, Kunming, China.
³Research Center of Tumor Palliative Medicine in Yunnan, Kunming, China.

ABSTRACT

Vulvar cancer is a rare female genital neoplasm representing 5% of all gynecological malignancies, and occurring most frequently in women between the ages of 65 and 75. The most common histological type is squamous cell carcinoma followed by melanoma, basal cell carcinoma, and adenocarcinoma. In the early disease stage, surgical treatment can be effective; however, once recurrence and metastasis occur, advanced vulvar cancer is often difficult to be treated. Overexpression, amplification, and mutations in epidermal growth factor receptor (EGFR) have been found in many types of cancer, including primary vulvar squamous cell carcinoma and metastatic lesions, and correlate with a poor prognosis. EGFR mutation detection has become a routine molecular test with significant implications for prognosis. Thus, the goal of this study was to learn more about EGFR gene somatic mutations in vulvar cancer and to determine whether EGFR-tyrosine kinase inhibitors (TKIs) have different efficacies in patients with and without EGFR mutations. The results showed that targeted therapy based on EGFR mutation status could significantly improve the prognosis of patients. Thus, molecular profiling to determine mutation status may be an initial step towards developing effective therapeutic regimens to treat advanced vulvar cancer.

KEYWORDS

Gefitinib, Prognosis, Response Rate, Survival

Share and Cite:

Liu, K. , Yang, Y. , Wang, C. , Wang, Y. and Zhu, Y. (2017) EGFR Mutation Status and TKI Therapy in Patients with Advanced Vulvar Cancer: Clinical Observations. Open Access Library Journal, 4, 1-10. doi: 10.4236/oalib.1103956.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies